In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin

Chinese Medical Journal

Volumn 123, Issue 19, 2010, Pages 2706-2709

  Shi, Jun Yan ^a   Xu, Ying Chun ^a   Shi, Yi ^b   Lü, Huo Xiang ^c   Liu, Yong ^d   Zhao, Wang Sheng ^e   Chen, Dong Mei ^f   Xi, Li Yan ^g   Zhou, Xin ^h   Wang, He ^a   Guo, Li Na ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^h SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Antifungal activity; Antifungal agents; Aspergillus; Drug resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONTROLLED STUDY; CULTURE MEDIUM; EPSILOMETER TEST; FUNGAL STRAIN; IN VITRO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; ECHINOCANDINS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 78149265758     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.19.016     Document Type: Article

References (13)

1. Liu W, Li RY. The role of antifungal susceptibility testing in medical mycology. Chin J Lab Med (Chin) 2005; 28:349-351.
2. Liu W, Li RY. Diagnostic laboratory test of deep fungal infections and antifungal susceptibility testing. Chin J Infect Chemother (Chin) 2007; 7: 289-292.
3. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-1904.
4. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003; 41: 1126-1129.
5. Serrano MC, Morilla D, Valverde A, Chávez M, Espinel-Ingroff A, Claro R, et al. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole. J Clin Microbiol 2003; 41: 5270-5272.
6. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45: 241-244.
7. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41: 403-409.
8. Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, et al. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents 2005; 25: 321-328.
9. Pfaller MA, Messer SA, Hollis RJ, Jones RN. SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-1037.
10. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13-16.
11. Patera AC, Menzel F, Jackson C, Brieland JK, Halpern J, Hare R, et al. Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48: 3154-3158.
12. Arendrup MC, Perkhofer S, Howard SJ, Garcia-Effron G, Vishukumar A, Perlin D, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-3511.
13. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-4066.